Evaluates the association between HALP score and kidney disease progression in chronic kidney disease patients, suggesting its potential as a clinical marker.
The hemoglobin, albumin, lymphocyte, and platelet (HALP) score, a composite biomarker reflecting nutritional and inflammatory status, was first proposed in 2015 as a prognostic indicator for survival in patients with gastric cancer (Chen et al., Oncotarget, 2015). Since then, the HALP score has been reported to be associated with poor prognosis in various chronic diseases. However, its clinical significance in patients with chronic kidney disease (CKD) remains unclear. The present study aimed to evaluate the association between HALP score and kidney disease progression in patients with CKD not on chronic dialysis.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: